Back to search results

Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients

Abroad (travel likely)RecruitingPHASE3

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

    Contact: Study coordinator (Serban Morojanu) · moroiasa@cinj.rutgers.edu · +1 732-235-7577
    Contact: Principal Investigator (Richard DRACHTMAN)

  • Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

    Contact: Study coordinator (Ariel Rivera) · riveraa12@chop.edu · +1 267 425 2136
    Contact: Principal Investigator (Timothy Olson)

  • St Jude Childrens Research Hospital, Memphis, Tennessee, United States

    Contact: Study coordinator (Kelsey Ray) · kelsey.ray@stjude.org
    Contact: Principal Investigator (Marcin Wlodarski)

  • Novartis Investigative Site, Brasília, Federal District, Brazil

  • Novartis Investigative Site, Natal, Rio Grande do Norte, Brazil

  • Novartis Investigative Site, Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site, Santo André, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, São Paulo, São Paulo, Brazil

  • Novartis Investigative Site, Cali, Valle del Cauca Department, Colombia

  • Novartis Investigative Site, Berlin, Germany

  • Novartis Investigative Site, Genova, GE, Italy

  • Novartis Investigative Site, Utrecht, Netherlands

Study leads

  • Novartis Pharmaceuticals

    Study Director

    Novartis Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)